{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saxagliptin&page=2",
    "query": {
      "intervention": "Saxagliptin",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saxagliptin&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-19T19:29:57.001Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02547935",
      "title": "A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus, CKD and Albuminuria"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Saxagliptin 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 459,
      "start_date": "2015-09-21",
      "completion_date": "2018-05-18",
      "has_results": true,
      "last_update_posted_date": "2019-08-21",
      "last_synced_at": "2026-09-19T19:29:57.001Z",
      "location_count": 37,
      "location_summary": "Peoria, Arizona • Chula Vista, California • Concord, California + 34 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "El Centro",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02547935"
    },
    {
      "nct_id": "NCT03936023",
      "title": "Replication of the SAVOR-TIMI Diabetes Trial in Healthcare Claims",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "Saxagliptin",
          "type": "DRUG"
        },
        {
          "name": "Sulfonylurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 182126,
      "start_date": "2017-09-22",
      "completion_date": "2021-02-18",
      "has_results": false,
      "last_update_posted_date": "2023-08-01",
      "last_synced_at": "2026-09-19T19:29:57.001Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03936023"
    },
    {
      "nct_id": "NCT02419612",
      "title": "A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "Saxagliptin",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Glimepiride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 444,
      "start_date": "2015-08-14",
      "completion_date": "2019-09-18",
      "has_results": true,
      "last_update_posted_date": "2020-06-23",
      "last_synced_at": "2026-09-19T19:29:57.001Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Tempe, Arizona + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02419612"
    },
    {
      "nct_id": "NCT02024477",
      "title": "Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Saxagliptin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "George Washington University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "40 Years to 70 Years"
      },
      "enrollment_count": 42,
      "start_date": "2013-11",
      "completion_date": "2017-12",
      "has_results": true,
      "last_update_posted_date": "2019-02-15",
      "last_synced_at": "2026-09-19T19:29:57.001Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02024477"
    },
    {
      "nct_id": "NCT01267448",
      "title": "Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus Type 2",
        "Hyperglycemia"
      ],
      "interventions": [
        {
          "name": "Glipizide XL",
          "type": "DRUG"
        },
        {
          "name": "Saxagliptin + Metformin XR",
          "type": "DRUG"
        },
        {
          "name": "Metformin XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cook County Health",
      "sponsor_class": "OTHER_GOV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 100,
      "start_date": "2014-09-09",
      "completion_date": "2015-07-25",
      "has_results": false,
      "last_update_posted_date": "2023-06-26",
      "last_synced_at": "2026-09-19T19:29:57.001Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01267448"
    },
    {
      "nct_id": "NCT01204775",
      "title": "Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Saxagliptin",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Saxagliptin)",
          "type": "DRUG"
        },
        {
          "name": "Metformin IR",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Metformin)",
          "type": "DRUG"
        },
        {
          "name": "Metformin (Active Rescue)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 26,
      "start_date": "2011-06",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2017-04-18",
      "last_synced_at": "2026-09-19T19:29:57.001Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • San Diego, California • Hollywood, Florida + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Tallahassee",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01204775"
    },
    {
      "nct_id": "NCT01619059",
      "title": "Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Saxagliptin",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Metformin IR",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching with Saxagliptin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 315,
      "start_date": "2012-06",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2016-04-22",
      "last_synced_at": "2026-09-19T19:29:57.001Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01619059"
    },
    {
      "nct_id": "NCT00897390",
      "title": "Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Saxagliptin",
          "type": "DRUG"
        },
        {
          "name": "Metformin IR (glucophage)",
          "type": "DRUG"
        },
        {
          "name": "Saxagliptin + Metformin IR (FDC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "19 Years to 45 Years"
      },
      "enrollment_count": 24,
      "start_date": "2009-06",
      "completion_date": "2009-07",
      "has_results": true,
      "last_update_posted_date": "2015-05-21",
      "last_synced_at": "2026-09-19T19:29:57.001Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00897390"
    },
    {
      "nct_id": "NCT01765270",
      "title": "Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus",
        "Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "Saxagliptin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "45 Years to 75 Years"
      },
      "enrollment_count": 12,
      "start_date": "2013-03",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2015-05-29",
      "last_synced_at": "2026-09-19T19:29:57.001Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Fort Smith, Arkansas + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01765270"
    },
    {
      "nct_id": "NCT07188545",
      "title": "Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cardiovascular Kidney Metabolic Syndrome"
      ],
      "interventions": [
        {
          "name": "Intervention",
          "type": "DRUG"
        },
        {
          "name": "Active Comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23280000,
      "start_date": "2025-09-15",
      "completion_date": "2029-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-09-23",
      "last_synced_at": "2026-09-19T19:29:57.001Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07188545"
    }
  ]
}